Adynxx (Adynxx) EBIT : $-6.28 Mil (TTM As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx EBIT?

Adynxx's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2019 was $-1.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2019 was $-6.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Adynxx's annualized ROC % for the quarter that ended in Sep. 2019 was -71.49%. Adynxx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -905.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Adynxx EBIT Historical Data

The historical data trend for Adynxx's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx EBIT Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EBIT

Get a 7-Day Free Trial

-25.43

-27.37

-31.21

-4.76

-5.30

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EBIT	Get a 7-Day Free Trial															-0.97	-1.38	-0.98	-2.25	-1.67

Competitive Comparison of Adynxx's EBIT

For the Biotechnology subindustry, Adynxx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adynxx's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Adynxx's EV-to-EBIT falls into.

Adynxx EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.28 Mil.

Adynxx (OTCPK:ADYX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Adynxx's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

	ROC % (Q: Sep. 2019 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2019 )	+	Invested Capital (Q: Sep. 2019 ))	/ count )
=	-6.688 * ( 1 - 0% )	/	( (9.036	+	9.675)	/ 2 )
=	-6.688	/	9.3555
=	-71.49 %

where

	Invested Capital		(Q: Jun. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.703	-	3.228	-	( 0.024	-	max(0, 11.461	-	1.9	+	0.024	))
=	9.036

	Invested Capital		(Q: Sep. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.254	-	4.832	-	( 0.331	-	max(0, 13.797	-	2.544	+	0.331	))
=	9.675

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Adynxx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2019 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2019		Q: Sep. 2019
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.688	/	( ( (0.785 + max(-1.352, 0))	+	(0.692 + max(-2.619, 0)) )	/	2 )
=	-6.688	/	( ( 0.785	+	0.692 )	/	2 )
=	-6.688	/	0.7385
=	-905.62 %

where Working Capital is:

	Working Capital		(Q: Jun. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.876)	-	(3.228	+	0	+	0)
=	-1.352

	Working Capital		(Q: Sep. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.213)	-	(4.832	+	0	+	0)
=	-2.619

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Adynxx's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2019 )
	=	-6.276	/	0.000
	=	%

Adynxx EBIT Related Terms

Thank you for viewing the detailed overview of Adynxx's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Adynxx (Adynxx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Executives

Gregory J. Flesher	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning	officer: CHIEF MEDICAL OFFICER	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair	10 percent owner	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu	10 percent owner
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102